CMBA
FLNA

C.M. Bidwell & Associates’s Filana Therapeutics FLNA Stock Holding History

C.M. Bidwell & Associates’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,404
Closed -$157K – 586
2023
Q2 		$157K Buy
+6,404
New +$154K 0.11% 151

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

C.M. Bidwell & Associates's FLNA Position: Q3 2023 in Review

C.M. Bidwell & Associates sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 6,404 shares — an estimated $157K sold.

C.M. Bidwell & Associates first reported a position in FLNA in Q2 2023 and held it in 1 quarter. The position peaked at $157K in Q2 2023. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

  • C.M. Bidwell & Associates reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 6,404 Filana Therapeutics shares in Q3 2023, an estimated $157K.
  • C.M. Bidwell & Associates first reported a position in Filana Therapeutics in Q2 2023 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Filana Therapeutics position peaked at $157K in Q2 2023.
  • 140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2023, filed 13 Nov 2023.